Cargando…

Lung Cancer Surgery after Neoadjuvant Immunotherapy

SIMPLE SUMMARY: Neoadjuvant immunotherapy is a novel approach for lung cancer patients in stages where curative intent treatment is possible. The rationale is a based on the idea that recognition by the immune system is activated by the entire tumor prior to surgical resection. Promising pathologic...

Descripción completa

Detalles Bibliográficos
Autores principales: Stefani, Dirk, Plönes, Till, Viehof, Jan, Darwiche, Kaid, Stuschke, Martin, Schuler, Martin, Aigner, Clemens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393473/
https://www.ncbi.nlm.nih.gov/pubmed/34439187
http://dx.doi.org/10.3390/cancers13164033
_version_ 1783743734220849152
author Stefani, Dirk
Plönes, Till
Viehof, Jan
Darwiche, Kaid
Stuschke, Martin
Schuler, Martin
Aigner, Clemens
author_facet Stefani, Dirk
Plönes, Till
Viehof, Jan
Darwiche, Kaid
Stuschke, Martin
Schuler, Martin
Aigner, Clemens
author_sort Stefani, Dirk
collection PubMed
description SIMPLE SUMMARY: Neoadjuvant immunotherapy is a novel approach for lung cancer patients in stages where curative intent treatment is possible. The rationale is a based on the idea that recognition by the immune system is activated by the entire tumor prior to surgical resection. Promising pathologic response rates have been reported and the impact on survival is currently investigated in ongoing studies. ABSTRACT: In early-stage lung cancer, recurrences are observed even after curative resection. Neoadjuvant immunotherapy might be a promising approach to eliminate micrometastasis and to potentially reduce recurrence rates and improve survival. Early trials have shown encouraging rates of pathologic response to neoadjuvant therapy and have demonstrated that surgery can be safely performed after neoadjuvant immunotherapy with various agents and in combination with chemo-(radio)therapy. However, whether these response rates translate into improved disease-free survival rates and overall survival rates remains to be determined by ongoing phase III studies.
format Online
Article
Text
id pubmed-8393473
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83934732021-08-28 Lung Cancer Surgery after Neoadjuvant Immunotherapy Stefani, Dirk Plönes, Till Viehof, Jan Darwiche, Kaid Stuschke, Martin Schuler, Martin Aigner, Clemens Cancers (Basel) Review SIMPLE SUMMARY: Neoadjuvant immunotherapy is a novel approach for lung cancer patients in stages where curative intent treatment is possible. The rationale is a based on the idea that recognition by the immune system is activated by the entire tumor prior to surgical resection. Promising pathologic response rates have been reported and the impact on survival is currently investigated in ongoing studies. ABSTRACT: In early-stage lung cancer, recurrences are observed even after curative resection. Neoadjuvant immunotherapy might be a promising approach to eliminate micrometastasis and to potentially reduce recurrence rates and improve survival. Early trials have shown encouraging rates of pathologic response to neoadjuvant therapy and have demonstrated that surgery can be safely performed after neoadjuvant immunotherapy with various agents and in combination with chemo-(radio)therapy. However, whether these response rates translate into improved disease-free survival rates and overall survival rates remains to be determined by ongoing phase III studies. MDPI 2021-08-10 /pmc/articles/PMC8393473/ /pubmed/34439187 http://dx.doi.org/10.3390/cancers13164033 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Stefani, Dirk
Plönes, Till
Viehof, Jan
Darwiche, Kaid
Stuschke, Martin
Schuler, Martin
Aigner, Clemens
Lung Cancer Surgery after Neoadjuvant Immunotherapy
title Lung Cancer Surgery after Neoadjuvant Immunotherapy
title_full Lung Cancer Surgery after Neoadjuvant Immunotherapy
title_fullStr Lung Cancer Surgery after Neoadjuvant Immunotherapy
title_full_unstemmed Lung Cancer Surgery after Neoadjuvant Immunotherapy
title_short Lung Cancer Surgery after Neoadjuvant Immunotherapy
title_sort lung cancer surgery after neoadjuvant immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393473/
https://www.ncbi.nlm.nih.gov/pubmed/34439187
http://dx.doi.org/10.3390/cancers13164033
work_keys_str_mv AT stefanidirk lungcancersurgeryafterneoadjuvantimmunotherapy
AT plonestill lungcancersurgeryafterneoadjuvantimmunotherapy
AT viehofjan lungcancersurgeryafterneoadjuvantimmunotherapy
AT darwichekaid lungcancersurgeryafterneoadjuvantimmunotherapy
AT stuschkemartin lungcancersurgeryafterneoadjuvantimmunotherapy
AT schulermartin lungcancersurgeryafterneoadjuvantimmunotherapy
AT aignerclemens lungcancersurgeryafterneoadjuvantimmunotherapy